These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 9225958)
21. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Coulthard SA; Hogarth LA; Little M; Matheson EC; Redfern CP; Minto L; Hall AG Mol Pharmacol; 2002 Jul; 62(1):102-9. PubMed ID: 12065760 [TBL] [Abstract][Full Text] [Related]
23. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532 [TBL] [Abstract][Full Text] [Related]
24. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro. Liliemark J; Pettersson B; Peterson C Leuk Res; 1992; 16(3):275-80. PubMed ID: 1373210 [TBL] [Abstract][Full Text] [Related]
25. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961 [TBL] [Abstract][Full Text] [Related]
26. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634 [TBL] [Abstract][Full Text] [Related]
28. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Erb N; Harms DO; Janka-Schaub G Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 6-mercaptopurine with 6-thioguanine for the analysis of thiopurine S-methyltransferase activity in human erythrocyte by LC-MS/MS. Mei S; Li X; Gong X; Zhang X; Li X; Yang L; Zhu L; Zhou H; Liu Y; Zhou A; Zhang X; Zhao Z Biomed Chromatogr; 2017 Sep; 31(9):. PubMed ID: 28212467 [TBL] [Abstract][Full Text] [Related]
31. The role of xanthine oxidase in thiopurine metabolism: a case report. Wong DR; Derijks LJ; den Dulk MO; Gemmeke EH; Hooymans PM Ther Drug Monit; 2007 Dec; 29(6):845-8. PubMed ID: 18043486 [TBL] [Abstract][Full Text] [Related]
32. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. Mardini HE; Arnold GL J Clin Gastroenterol; 2003; 36(5):390-5. PubMed ID: 12702978 [TBL] [Abstract][Full Text] [Related]
33. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Hogarth LA; Redfern CP; Teodoridis JM; Hall AG; Anderson H; Case MC; Coulthard SA Biochem Pharmacol; 2008 Oct; 76(8):1024-35. PubMed ID: 18708030 [TBL] [Abstract][Full Text] [Related]
34. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Estlin EJ Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928 [TBL] [Abstract][Full Text] [Related]
35. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Kwan LY; Devlin SM; Mirocha JM; Papadakis KA Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898 [TBL] [Abstract][Full Text] [Related]
36. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300 [TBL] [Abstract][Full Text] [Related]
37. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. Hindorf U; Jahed K; Bergquist A; Verbaan H; Prytz H; Wallerstedt S; Werner M; Olsson R; Björnsson E; Peterson C; Almer SH J Hepatol; 2010 Jan; 52(1):106-11. PubMed ID: 19906459 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. Welch J; Lennard L; Morton GC; Lilleyman JS Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376 [TBL] [Abstract][Full Text] [Related]
39. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176 [TBL] [Abstract][Full Text] [Related]
40. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Gilissen LP; Derijks LJ; Verhoeven HM; Bierau J; Hooymans PM; Hommes DW; Engels LG Dig Liver Dis; 2007 Feb; 39(2):182-6. PubMed ID: 16880012 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]